| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(15)01123-X |
| P698 | PubMed publication ID | 26897598 |
| P50 | author | Flora Peyvandi | Q39183632 |
| P2093 | author name string | Guy Young | |
| Isabella Garagiola | |||
| P2860 | cites work | F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis | Q26827191 |
| Origins and Mechanisms of miRNAs and siRNAs | Q27860822 | ||
| Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A | Q28117400 | ||
| Sites of initial bleeding episodes, mode of delivery and age of diagnosis in babies with haemophilia diagnosed before the age of 2 years: a report from The Centers for Disease Control and Prevention's (CDC) Universal Data Collection (UDC) project | Q33488039 | ||
| Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment | Q33535682 | ||
| Noninvasive fetal sex determination using cell-free fetal DNA: a systematic review and meta-analysis | Q34028063 | ||
| Efficient production of dual recombinant adeno-associated viral vectors for factor VIII delivery | Q34082003 | ||
| Perinatal management of newborns with haemophilia | Q34135323 | ||
| The hemophilias--from royal genes to gene therapy | Q34276237 | ||
| A CpG mutational hotspot in a ONECUT binding site accounts for the prevalent variant of hemophilia B Leyden | Q34331863 | ||
| Hemophilia B Leyden and once mysterious cis-regulatory mutations | Q34378589 | ||
| Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. | Q34436796 | ||
| Recovery from Hemophilia B Leyden: An Androgen-Responsive Element in the Factor IX Promoter | Q34471218 | ||
| Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011 | Q34580100 | ||
| Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia | Q34661163 | ||
| Genetic sequence analysis of inherited bleeding diseases | Q34663589 | ||
| Haemophilia B mutations in Sweden: a population-based study of mutational heterogeneity | Q45876762 | ||
| Mutation analysis of haemophilia B in the Irish population: increased prevalence caused by founder effect | Q45877553 | ||
| Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy | Q45879749 | ||
| Guidelines for the management of hemophilia | Q45880345 | ||
| Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. | Q45880382 | ||
| Analysis of mRNA in hemophilia A patients with undetectable mutations reveals normal splicing in the factor VIII gene. | Q45880854 | ||
| The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy | Q45881127 | ||
| Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX. | Q45881987 | ||
| Recurrent inversion breaking intron 1 of the factor VIII gene is a frequent cause of severe hemophilia A. | Q45882168 | ||
| A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model | Q45882197 | ||
| Identification of deletion carriers in hemophilia B: quantitative real-time polymerase chain reaction or multiple ligation probe amplification | Q45883198 | ||
| Short-term low-dose secondary prophylaxis for severe/moderate haemophilia A children is beneficial to reduce bleed and improve daily activity, but there are obstacle in its execution: a multi-centre pilot study in China | Q45883686 | ||
| Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. | Q45884927 | ||
| Identification of de novo deletion in the factor VIII gene by MLPA technique in two girls with isolated factor VIII deficiency | Q45885124 | ||
| Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors | Q45885613 | ||
| Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed. | Q45886344 | ||
| Identification of factor VIII gene mutations in 101 patients with haemophilia A: mutation analysis by inversion screening and multiplex PCR and CSGE and molecular modelling of 10 novel missense substitutions | Q45886376 | ||
| Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. | Q45886921 | ||
| Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. | Q45889455 | ||
| Rituximab for treatment of inhibitors in haemophilia A. A Phase II study. | Q49866575 | ||
| Aptamers as therapeutics. | Q51813594 | ||
| Haemophilia A mutations in patients with non-severe phenotype associated with a discrepancy between one-stage and chromogenic factor VIII activity assays. | Q53071200 | ||
| Inhibitor development in non-severe haemophilia across Europe. | Q53378171 | ||
| Presence of fetal DNA in maternal plasma and serum | Q57075132 | ||
| Inhibitor development in haemophilia according to concentrate | Q59468965 | ||
| Preimplantation genetic diagnosis | Q80093090 | ||
| Characterisation of 96 mutations in 128 unrelated severe haemophilia A patients from France. Description of 62 novel mutations | Q83120292 | ||
| Fetal loss rate after chorionic villus sampling and amniocentesis: an 11-year national registry study | Q84018877 | ||
| Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial | Q34737483 | ||
| Long-term safety and efficacy of factor IX gene therapy in hemophilia B. | Q34783922 | ||
| Consensus perspectives on prophylactic therapy for haemophilia: summary statement | Q35112424 | ||
| Standardization of FVIII & FIX assays | Q35163622 | ||
| Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. | Q35181684 | ||
| Adenovirus-associated virus vector-mediated gene transfer in hemophilia B | Q35691659 | ||
| A cross-sectional study of bleeding phenotype in haemophilia A carriers | Q35812405 | ||
| Hemophilia B: molecular pathogenesis and mutation analysis. | Q35832802 | ||
| Hemophilic arthropathy | Q35912735 | ||
| Monitoring haemophilia severity and treatment: new or old laboratory tests? | Q35915695 | ||
| Inhibitors in congenital coagulation disorders | Q35937076 | ||
| Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. | Q36250920 | ||
| Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients | Q36380181 | ||
| Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant | Q36797248 | ||
| Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience | Q36819965 | ||
| How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults | Q36867591 | ||
| Improved treatment feasibility in children with hemophilia using arteriovenous fistulae: the results after seven years of follow-up | Q37175598 | ||
| Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. | Q37489013 | ||
| Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide | Q37634856 | ||
| Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review | Q37719683 | ||
| Blood-induced joint disease: the pathophysiology of hemophilic arthropathy | Q37768520 | ||
| Discrepancy between one-stage and chromogenic factor VIII activity assay results can lead to misdiagnosis of haemophilia A phenotype. | Q37807879 | ||
| Guideline on the management of haemophilia in the fetus and neonate | Q37873540 | ||
| Parallel use of by-passing agents in haemophilia with inhibitors: a critical review | Q37927122 | ||
| The diagnosis and management of congenital hemophilia | Q38046535 | ||
| More than a decade of international experience with a pdFVIII/VWF concentrate in immune tolerance | Q38070812 | ||
| Factor VIII inhibitors in hemophilia A: rationale and latest evidence | Q38101041 | ||
| FEIBA versus NovoSeven in hemophilia patients with inhibitors | Q38135321 | ||
| Hemophilia a and hemophilia B: different types of diseases? | Q38135323 | ||
| Arthropathy in patients with moderate hemophilia a: a systematic review of the literature | Q38136140 | ||
| Inhibitor eradication with rituximab in haemophilia: where do we stand? | Q38195908 | ||
| Current status of haemophilia gene therapy | Q38206852 | ||
| Innovative approach for improved rFVIII concentrate | Q38207134 | ||
| Prophylaxis with FEIBA in paediatric patients with haemophilia A and inhibitors | Q38325328 | ||
| 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases | Q39433082 | ||
| Personalized prophylaxis | Q39596251 | ||
| Inhibitor development and mortality in non-severe hemophilia A. | Q41014569 | ||
| Impact of inhibitors on hemophilia A mortality in the United States. | Q41524981 | ||
| Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. | Q41975229 | ||
| The Fc gamma receptor IIa R131H polymorphism is associated with inhibitor development in severe hemophilia A. | Q42211106 | ||
| A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study | Q42598903 | ||
| A microRNA-regulated and GP64-pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of Hemophilia A. | Q42709633 | ||
| Factor VIII products and inhibitor development in severe hemophilia A. | Q43770114 | ||
| "Founder" effect in different families with haemophilia B mutation | Q43815426 | ||
| Changing patterns of bleeding in patients with severe haemophilia A. | Q44584056 | ||
| F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity | Q44646272 | ||
| Physical functioning in boys with hemophilia in the U.S. | Q44715249 | ||
| Inhibitors occur more frequently in African-American and Latino haemophiliacs | Q45855283 | ||
| Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. | Q45855813 | ||
| Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. | Q45855994 | ||
| Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile | Q45856559 | ||
| Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. | Q45858690 | ||
| Clinical use of a new glycine-precipitated antihemophilic fraction | Q45859062 | ||
| Production of High-Potency Concentrates of Antihemophilic Globulin in a Closed-Bag System | Q45859073 | ||
| Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF-containing plasma-derived FVIII concentrate. | Q45859168 | ||
| Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. | Q45861960 | ||
| Spectrum of molecular defects and mutation detection rate in patients with mild and moderate hemophilia A. | Q45862416 | ||
| The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial | Q45864000 | ||
| Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. | Q45865637 | ||
| Similar bleeding phenotype in young children with haemophilia A or B: a cohort study | Q45865672 | ||
| Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. | Q45865894 | ||
| A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). | Q45866554 | ||
| Trends in bleeding patterns during prophylaxis for severe haemophilia: observations from a series of prospective clinical trials | Q45866876 | ||
| Comparing bleed frequency and factor concentrate use between haemophilia A and B patients | Q45867613 | ||
| Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A. | Q45868849 | ||
| AIDS, hepatitis and hemophilia in the 1980s: memoirs from an insider | Q45869176 | ||
| Non-invasive tool for foetal sex determination in early gestational age. | Q45869375 | ||
| Phenotypic heterogeneity in severe hemophilia | Q45869550 | ||
| Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors | Q45870481 | ||
| A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group | Q45870861 | ||
| Prenatal diagnosis and preimplantation genetic diagnosis: novel technologies and state of the art of PGD in different regions of the world | Q45871116 | ||
| European study on orthopaedic status of haemophilia patients with inhibitors | Q45871281 | ||
| Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial | Q45872638 | ||
| Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison | Q45873703 | ||
| Evaluation of DHPLC in the analysis of hemophilia A. | Q45874440 | ||
| Identification of 217 unreported mutations in the F8 gene in a group of 1,410 unselected Italian patients with hemophilia A. | Q45874679 | ||
| Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors | Q45874687 | ||
| The principal results of the International Immune Tolerance Study: a randomized dose comparison | Q45875180 | ||
| Neonatal bleeding in haemophilia: a European cohort study | Q45875593 | ||
| The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. | Q45876258 | ||
| P433 | issue | 10040 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hemophilia | Q134003 |
| P304 | page(s) | 187-197 | |
| P577 | publication date | 2016-02-18 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | The past and future of haemophilia: diagnosis, treatments, and its complications | |
| P478 | volume | 388 |
| Q92044581 | "The times they are a-changin", ... or maybe not? |
| Q36356147 | Acquired hemophilia A: a review of recent data and new therapeutic options |
| Q38945123 | Advances in the treatment of bleeding disorders. |
| Q45873084 | Analyses of the FranceCoag cohort support immunogenicity differences among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A. |
| Q57289034 | Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia |
| Q97519097 | B Cell Depletion Eliminates FVIII Memory B Cells and Enhances AAV8-coF8 Immune Tolerance Induction When Combined With Rapamycin |
| Q38941572 | BAY 81-8973 (Octocog Alfa; Kovaltry®): A Review in Haemophilia A. |
| Q90516253 | Blood coagulation dissected |
| Q88732008 | Blood-induced bone loss in murine hemophilic arthropathy is prevented by blocking the iRhom2/ADAM17/TNF-α pathway |
| Q90674195 | Clinical utility and impact of the use of the chromogenic vs one-stage factor activity assays in haemophilia A and B |
| Q39042380 | Coagulation Factor IX (Recombinant), Albumin Fusion Protein (Albutrepenonacog Alfa; Idelvion®): A Review of Its Use in Haemophilia B. |
| Q92433809 | Comparison of 90-Day Complication Rates and Cost Between Single and Multiple Joint Procedures for End-Stage Arthropathy in Patients with Hemophilia |
| Q104289829 | Current Clinical Applications of in vivo Gene Therapy with AAVs |
| Q91788836 | Developing a new scoring scheme for the Hemophilia Joint Health Score 2.1. |
| Q28075679 | Different impact of factor VIII products on inhibitor development? |
| Q64046774 | Drug discovery and development for rare genetic disorders |
| Q38720560 | Efficacy and safety of a recombinant factor VIII produced from a human cell line (simoctocog alfa). |
| Q38917306 | Efmoroctocog Alfa: A Review in Haemophilia A. |
| Q38711095 | Eftrenonacog Alfa: A Review in Haemophilia B. |
| Q38822601 | Elucidation of Factor VIII Activity Pharmacokinetics: A Pooled Population Analysis in Patients With Hemophilia A Treated With Moroctocog Alfa |
| Q93073557 | Emicizumab for the treatment of haemophilia A: a narrative review |
| Q64376622 | Evaluation of the activity levels of rat FVIII and human FVIII delivered by adeno-associated viral vectors both in vitro and in vivo |
| Q52666862 | Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens. |
| Q99404325 | Foot health-related quality of life in hemophiliacs: A case-control study |
| Q91914674 | Functions of the Heterologous Intron-Derived Fragments Intra and Extra Factor IX-cDNA Coding Region on the Human Factor IX Expression in HepG2 and Hek-293T Cells |
| Q36290952 | Genome editing for inborn errors of metabolism: advancing towards the clinic. |
| Q89722194 | Hemophilia therapy: the future has begun |
| Q57795848 | Implementing emicizumab in hemophilia inhibitor management: emicizumab should be prescribed after tolerance |
| Q38950767 | Incidence of low-titre factor VIII inhibitors in patients with haemophilia A: meta-analysis of observational studies |
| Q98292034 | Induction of ER Stress by an AAV5 BDD FVIII Construct Is Dependent on the Strength of the Hepatic-Specific Promoter |
| Q55346403 | Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab. |
| Q45874801 | Management of Hemophilia in Older Patients |
| Q45874959 | Modern Treatments of Haemophilia: Review of Cost-Effectiveness Analyses and Future Directions |
| Q52378729 | Molecular mechanisms of missense mutations that generate ectopic N-glycosylation sites in coagulation factor VIII. |
| Q39027887 | New therapies for hemophilia |
| Q90197782 | Next-generation regulatory T cell therapy |
| Q45874270 | Nonacog Beta Pegol: A Review in Haemophilia B. |
| Q45864205 | Oral Tolerance Induction in Hemophilia B Dogs Fed with Transplastomic Lettuce |
| Q90180915 | Oral and Psychological Alterations in Haemophiliac Patients |
| Q37292357 | Overexpression of factor VIII after AAV delivery is transiently associated with cellular stress in hemophilia A mice |
| Q92345043 | Prednisolone Does Not Regulate Factor VIII Expression in Mice Receiving AAV5-hFVIII-SQ: Valoctocogene Roxaparvovec |
| Q61040433 | Product type and other environmental risk factors for inhibitor development in severe hemophilia A |
| Q39170433 | Production of recombinant coagulation factors: Are humans the best host cells? |
| Q61811175 | Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy |
| Q42090919 | Repeated Diffuse Alveolar Hemorrhage in a Patient with Hemophilia B. |
| Q91717369 | Superhydrophobic hemostatic nanofiber composites for fast clotting and minimal adhesion |
| Q37695999 | Systemic delivery of factor IX messenger RNA for protein replacement therapy |
| Q38828174 | Tailoring hemostatic therapies to lower inhibitor development in previously untreated patients with severe hemophilia A. |
| Q96348307 | Targeted inhibition of activated protein C by a non-active-site inhibitory antibody to treat hemophilia |
| Q45873688 | Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis |
| Q45875066 | Total Hip Arthroplasty in Hemophilia Patients: A Mid-term to Long-term Follow-up |
| Q95271852 | Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A |
| Q45874991 | Trenonacog alfa for prophylaxis, on-demand and perioperative management of hemophilia B. |
| Q41922244 | Two-incision laparoscopic appendectomy for a severe hemophilia A child patient with coagulation factor VII deficiency: Case report and review of literature |
| Q45875860 | Vaccinations are not associated with inhibitor development in boys with severe haemophilia A. |
| Q100750470 | X Chromosome inactivation: a modifier of factor VIII and IX plasma levels and bleeding phenotype in Haemophilia carriers |
| Q50610450 | [Retrospectively analysis of the difference of bleeding frequency and hemophilic arthropathy between hemophilia A and hemophilia B patients]. |
Search more.